Display options
Cite
Schmucker J, Fach A, Osteresch R, et al. Efficacy of Drug-Eluting Stents in Diabetic Patients Admitted with ST-Elevation Myocardial Infarctions Treated with Primary Percutaneous Coronary Intervention. J Cardiovasc Dev Dis. 2021;8(8)doi: 10.3390/jcdd8080083.
Schmucker, J., Fach, A., Osteresch, R., Mata Marin, L. A., Ruehle, S., Retzlaff, T., Garstka, D., Eitel, I., Hambrecht, R., & Wienbergen, H. (2021). Efficacy of Drug-Eluting Stents in Diabetic Patients Admitted with ST-Elevation Myocardial Infarctions Treated with Primary Percutaneous Coronary Intervention. Journal of cardiovascular development and disease, 8(8), . https://doi.org/10.3390/jcdd8080083
Schmucker, Johannes, et al. "Efficacy of Drug-Eluting Stents in Diabetic Patients Admitted with ST-Elevation Myocardial Infarctions Treated with Primary Percutaneous Coronary Intervention." Journal of cardiovascular development and disease vol. 8,8 (2021). doi: https://doi.org/10.3390/jcdd8080083
Schmucker J, Fach A, Osteresch R, Mata Marin LA, Ruehle S, Retzlaff T, Garstka D, Eitel I, Hambrecht R, Wienbergen H. Efficacy of Drug-Eluting Stents in Diabetic Patients Admitted with ST-Elevation Myocardial Infarctions Treated with Primary Percutaneous Coronary Intervention. J Cardiovasc Dev Dis. 2021 Jul 21;8(8). doi: 10.3390/jcdd8080083. PMID: 34436225; PMCID: PMC8397182.
Copy Download .nbib Format: NLM
Share it on

J Cardiovasc Dev Dis. 2021 Jul 21;8(8). doi: 10.3390/jcdd8080083.

Efficacy of Drug-Eluting Stents in Diabetic Patients Admitted with ST-Elevation Myocardial Infarctions Treated with Primary Percutaneous Coronary Intervention.

Journal of cardiovascular development and disease

Johannes Schmucker, Andreas Fach, Rico Osteresch, Luis Alberto Mata Marin, Stephan Ruehle, Tina Retzlaff, Daniela Garstka, Ingo Eitel, Rainer Hambrecht, Harm Wienbergen

Affiliations

  1. Bremen Institute for Heart and Circulation Research, 28277 Bremen, Germany.
  2. Medical Clinic II, University Heart Center, 23562 Lübeck, Germany.

PMID: 34436225 PMCID: PMC8397182 DOI: 10.3390/jcdd8080083

Abstract

BACKGROUND: Diabetic patients show higher adverse ischemic event rates and mortality when undergoing percutaneous coronary intervention (PCI) in acute myocardial infarctions. Therefore, diabetic patients might benefit even more from modern-generation drug-eluting stents (DES). The aim of the present study was to compare adverse ischemic events and mortality rates between bare-metal stents (BMS) and DES in diabetic patients admitted with ST-elevation-myocardial infarction (STEMI) with non-diabetic patients as the control group.

METHODS: All STEMI patients undergoing emergency PCI and stent implantation documented between 2006 and 2019 in the Bremen STEMI registry entered the analysis. Efficacy was defined as a combination of in-stent thrombosis, myocardial re-infarction or additional target lesion revascularization at one year.

RESULTS: Of 8356 patients which entered analysis, 1554 (19%) were diabetics, while 6802 (81%) were not. 879 (57%) of the diabetics received a DES. In a multivariate model, DES implantation in diabetics compared to BMS was associated with lower rates of in-stent thrombosis (OR 0.16, 95% CI 0.05-0.6), myocardial re-infarctions (OR 0.35, 95%CI, 0.2-0.7,

CONCLUSIONS: In STEMI patients with diabetes, the use of DES significantly reduced ischemic event rates and, unlike with BMS, adverse ischemic event rates became similar to non-diabetic patients.

Keywords: STEMI; coronary artery disease; diabetes mellitus; drug-eluting stents

References

  1. N Engl J Med. 2016 Sep 29;375(13):1242-52 - PubMed
  2. J Am Coll Cardiol. 2019 Feb 19;73(6):629-638 - PubMed
  3. N Engl J Med. 2012 Dec 20;367(25):2375-84 - PubMed
  4. JAMA. 2007 Aug 15;298(7):765-75 - PubMed
  5. Am J Cardiol. 2010 Mar 15;105(6):819-25 - PubMed
  6. Eur Heart J. 2004 Feb;25(3):190-8 - PubMed
  7. Eur Heart J Acute Cardiovasc Care. 2018 Dec;7(8):710-722 - PubMed
  8. Clin Res Cardiol. 2018 May;107(5):371-379 - PubMed
  9. Neth Heart J. 2010 Aug;18(7-8):348-54 - PubMed
  10. Circ Cardiovasc Interv. 2014 Jun;7(3):355-64 - PubMed
  11. Eur Heart J. 2018 Jan 7;39(2):119-177 - PubMed
  12. Nat Rev Endocrinol. 2018 Feb;14(2):88-98 - PubMed
  13. Circulation. 2000 Oct 24;102(17):2031-7 - PubMed
  14. Catheter Cardiovasc Interv. 2008 Dec 1;72(7):909-14 - PubMed
  15. J Am Coll Cardiol. 2002 Sep 4;40(5):946-53 - PubMed
  16. Eur Heart J. 2013 Mar;34(10):729-41 - PubMed
  17. JAMA. 2000 Aug 16;284(7):835-42 - PubMed
  18. Am J Cardiol. 2015 Dec 15;116(12):1802-9 - PubMed
  19. Eur Heart J. 2010 Dec;31(24):3006-16 - PubMed
  20. BMC Cardiovasc Disord. 2017 Sep 22;17(1):254 - PubMed
  21. N Engl J Med. 1998 Jul 23;339(4):229-34 - PubMed
  22. PLoS One. 2016 Apr 25;11(4):e0154064 - PubMed
  23. N Engl J Med. 2015 Mar 26;372(13):1204-12 - PubMed
  24. J Am Heart Assoc. 2019 Sep 17;8(18):e012530 - PubMed
  25. Cardiovasc Diabetol. 2018 Jun 8;17(1):83 - PubMed
  26. J Interv Cardiol. 2017 Aug;30(4):301-308 - PubMed
  27. Circulation. 2008 Oct 14;118(16):1626-36 - PubMed
  28. BMJ. 2006 Nov 25;333(7578):1091 - PubMed
  29. J Am Coll Cardiol. 1998 Dec;32(7):1866-73 - PubMed
  30. Clin Res Cardiol. 2014 May;103(5):373-80 - PubMed
  31. Catheter Cardiovasc Interv. 2020 Aug;96(2):298-308 - PubMed
  32. Atherosclerosis. 2010 Jun;210(2):516-20 - PubMed
  33. Eur J Prev Cardiol. 2014 Sep;21(9):1180-6 - PubMed
  34. Diabetol Metab Syndr. 2017 Apr 4;9:21 - PubMed
  35. JAMA. 2012 Aug 22;308(8):777-87 - PubMed
  36. Eur Heart J. 2019 Jun 21;40(24):1909-1919 - PubMed

Publication Types